Navigation Links
Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development
Date:6/17/2009

Nearly 200 Quantitative Immunoassays for Discovery and Validation of New Biomarker Panels

AUSTIN, Texas, June 17 /PRNewswire/ -- Rules-Based Medicine, Incorporated (RBM), the world's leading multiplexed biomarker testing laboratory, today announced the availability of the most comprehensive collection of quantitative immunoassays for use in advancing safety, efficacy and efficiency in drug and diagnostic development. The new service, DiscoveryMAP(TM) v 1.0, offers customers dynamic coverage of most physiologically relevant pathways, providing biological information and leads for further study. This unique and comprehensive offering increases the odds of identifying new protein biomarker patterns in almost any drug development or diagnostic discovery project.

"Despite the known benefits of biomarkers in drug development, many biomarker discovery efforts fail to contribute because the patterns do not reproduce on a clinically validated platform. The RBM approach is to discover new biomarker patterns on the same platform that will be used in clinical trials," said Craig Benson, RBM chief executive officer. "DiscoveryMAP(TM) was designed in collaboration with our pharmaceutical and biotech customers and includes biomarkers known to be important in the major disease indications for drug development. Once a pattern is discovered, we can seamlessly convert those biomarkers into a new custom panel for high-throughput sample processing."

DiscoveryMAP(TM) v 1.0 utilizes RBM's proprietary multi-analyte profiling (MAP) platform to quantify key blood-based biomarkers representing dozens of important biological pathways.

DiscoveryMAP(TM) provides customers with the most robust, quantitative data compared to any available proteomic service or platform technology. All samples are processed in RBM's CLIA-certified lab using proprietary reagents and software to give the most accurate and reproducible protein measurements. Multiplexing allows all of these assays to be processed from a 500 microliter sample of serum or plasma, compared with single-plex platforms, such as ELISA, which would require upwards of 10 to 15 milliliters of sample. DiscoveryMAP(TM) samples are processed on an industrialized, automated platform that enables the discovery of biomarker patterns made up of multiple proteins, many with small, yet reproducibly detected, changes. New patterns can then be converted to a custom focused biomarker panel for high-throughput processing in clinical trials as a service from RBM or supplied to the customer as an optimized kit manufactured under Good Manufacturing Practice regulations.

DiscoveryMAP(TM) has already been successfully used in the discovery of new diagnostic biomarker panels. RBM's partnerships with Psynova Neurotech, Satoris, Inc., and leading academic researchers have yielded diagnostic biomarker patterns that have been validated with multi-site sample collections for applications such as neuropsychiatry, neurodegenerative disease, nephrology, immunology and cardiology. RBM is also partnering with several pharmaceutical companies to develop companion diagnostic products. The Company is seeking additional collaborations to develop diagnostic and companion diagnostic applications based on patterns detected with DiscoveryMAP(TM).

Drug developers have increasingly turned to the use of biomarkers in order to increase efficiency and reduce cost and risk. Researchers require sensitive and quantitative data to pinpoint the biomarker patterns that are either directly involved in the disease process or are useful surrogate markers. When those patterns can be reliably measured, the efficiency of drug development is accelerated while achieving greater efficacy and safety. By quantifying nearly 200 important blood proteins, DiscoveryMAP(TM) represents an important tool for biomarker discovery.

About Rules-Based Medicine

Rules-Based Medicine (RBM) provides comprehensive protein biomarker products and services centered on its Multi-Analyte Profiling (MAP) technology. Its service platform (RodentMAP(R) and HumanMAP(R)) provides pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins cost-effectively in multiple species, and from a small sample volume. The Company also offers innovative and proprietary ex vivo testing systems such as TruCulture(TM), the first fully-closed, reproducible whole blood culture system. RBM is actively developing multiplex diagnostic tests to detect the presence of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. More information about RBM is located at www.rulesbasedmedicine.com.

RodentMAP(R) and HumanMAP(R) are registered trademarks of Rules-Based Medicine Inc.


'/>"/>
SOURCE Rules-Based Medicine, Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
2. Council for American Medical Innovation Brings U.S. Leaders in Medicine, Biotechnology and Discovery Together in Chicago for Best and Brightest Forum on Medical Innovation
3. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
4. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
5. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
6. Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities
7. Drug Information Association Launches New 45th Annual Meeting Online
8. ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation and Fragment Screening on Its Octet(R) Platform
9. Smith & Nephew Endoscopy Launches the BICEPTOR(TM) Tenodesis System, the First All-Arthroscopic Procedure for Biceps Tendon Repair
10. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
11. Bioniche Pharma Launches Enlon(R) and Enlon-Plus(R) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... , June 24, 2016  Regular discussions on a ... take place between the two entities said Poloz. ... Ottawa , he pointed to the country,s ... the federal government. ... said, "Both institutions have common economic goals, why not sit ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):